IMRX vs. FIXX, SCYX, RPHM, VAXX, GANX, KZR, GMTX, JAGX, DARE, and APLM
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Homology Medicines (FIXX), SCYNEXIS (SCYX), Reneo Pharmaceuticals (RPHM), Vaxxinity (VAXX), Gain Therapeutics (GANX), Kezar Life Sciences (KZR), Gemini Therapeutics (GMTX), Jaguar Health (JAGX), Daré Bioscience (DARE), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.
Immuneering (NASDAQ:IMRX) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
67.7% of Immuneering shares are owned by institutional investors. Comparatively, 31.3% of Homology Medicines shares are owned by institutional investors. 23.0% of Immuneering shares are owned by company insiders. Comparatively, 16.1% of Homology Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Immuneering currently has a consensus price target of $13.50, indicating a potential upside of 800.00%. Homology Medicines has a consensus price target of $0.75, indicating a potential upside of ∞. Given Homology Medicines' higher probable upside, analysts plainly believe Homology Medicines is more favorable than Immuneering.
Homology Medicines received 102 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 64.43% of users gave Homology Medicines an outperform vote while only 60.53% of users gave Immuneering an outperform vote.
In the previous week, Immuneering's average media sentiment score of 0.00 equaled Homology Medicines'average media sentiment score.
Immuneering has a net margin of 0.00% compared to Homology Medicines' net margin of -4,779.31%. Immuneering's return on equity of -52.49% beat Homology Medicines' return on equity.
Immuneering has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
Immuneering has higher earnings, but lower revenue than Homology Medicines. Immuneering is trading at a lower price-to-earnings ratio than Homology Medicines, indicating that it is currently the more affordable of the two stocks.
Summary
Immuneering beats Homology Medicines on 8 of the 14 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
